Last updated on February 2018

A Study of GDC-0134 to Determine Initial Safety Tolerability and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis


Brief description of study

This first-in-human, double-blind, placebo-controlled Phase I study will be conducted in participants with amyotrophic lateral sclerosis (ALS) to explore safety, tolerability, and pharmacokinetic (PK) properties of GDC-0134. It will include two components: a Single-Ascending-Dose (SAD) stage and a Multiple-Ascending-Dose (MAD) stage.

Clinical Study Identifier: NCT02655614

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: GN29823 ...

Forbes Norris Mda/als Ctr; Research Center
San Francisco, CA United States
  Connect »

Reference Study ID Number: GN29823 ...

Mayo Clinic Hospital - Florida
Jacksonville, FL United States
  Connect »

Reference Study ID Number: GN29823 ...

University of Miami Miller School of Medicine
Miami, FL United States
  Connect »

Reference Study ID Number: GN29823 ...

Compass Research
Orlando, FL United States
  Connect »

Reference Study ID Number: GN29823 ...

The Emory ALS Clinic
Atlanta, GA United States
  Connect »

Reference Study ID Number: GN29823 ...

Johns Hopkins University School of Medicine
Baltimore, MD United States
  Connect »

Reference Study ID Number: GN29823 ...

Massachusetts General Hospital
Boston, MA United States
  Connect »

Reference Study ID Number: GN29823 ...

Wake Research Associates
Raleigh, NC United States
  Connect »

Reference Study ID Number: GN29823 ...

New Orleans Center for Clinical Research
Knoxville, TN United States
  Connect »

Reference Study ID Number: GN29823 ...

Methodist Neurological Institute
Houston, TX United States
  Connect »

Reference Study ID Number: GN29823 ...

MUCH - Montreal Neurological Institute & Hospital
Montreal, QC Canada
  Connect »